Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Myospas is a fixed-dose combination tablet containing chlorzoxazone (250 mg) and paracetamol (500 mg), designed for the treatment of pain associated with muscle spasms and various musculoskeletal conditions. Chlorzoxazone is a centrally-acting muscle relaxant that works by inhibiting multisynaptic reflex arcs at the spinal cord and subcortical levels, primarily through the enhancement of GABAergic neurotransmission. Paracetamol (acetaminophen) serves as an analgesic and antipyretic by inhibiting prostaglandin synthesis, particularly within the central nervous system. Together, these components provide synergistic relief for conditions such as back pain, neck pain, sprains, and joint pain associated with osteoarthritis or rheumatoid arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Myospas.